23.17
Sanara Medtech Inc stock is traded at $23.17, with a volume of 45,370.
It is down -1.99% in the last 24 hours and up +16.08% over the past month.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
See More
Previous Close:
$23.64
Open:
$23.7
24h Volume:
45,370
Relative Volume:
0.79
Market Cap:
$212.33M
Revenue:
$103.14M
Net Income/Loss:
$-5.82M
P/E Ratio:
-5.3233
EPS:
-4.3526
Net Cash Flow:
$2.14M
1W Performance:
+10.02%
1M Performance:
+16.08%
6M Performance:
+18.94%
1Y Performance:
-25.23%
Sanara Medtech Inc Stock (SMTI) Company Profile
Name
Sanara Medtech Inc
Sector
Industry
Phone
817-529-2300
Address
1200 SUMMIT AVE, FORT WORTH
Compare SMTI vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SMTI
Sanara Medtech Inc
|
23.17 | 216.64M | 103.14M | -5.82M | 2.14M | -4.3526 |
|
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Sanara Medtech Inc Stock (SMTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Lake Street | Buy |
| Mar-26-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| May-20-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jun-30-21 | Initiated | Cantor Fitzgerald | Overweight |
Sanara Medtech Inc Stock (SMTI) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc. (SMTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Shareholders to Connect - ACCESS Newswire
Sanara MedTech (SMTI) Q1 2026 Earnings Beat: Revenue $N/A, EPS $0.05Viral Trade Signals - Newser
Sanara MedTech (SMTI) Q1 2026 Earnings: EPS $0.05 Beats EstimatesEarnings Call Q&A - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc.SMTI - PR Newswire
Pomerantz LLP investigates Sanara MedTech for p... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sanara MedTech (SMTI) CEO reports share withholding to cover tax on vested stock - Stock Titan
Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
The Technical Signals Behind (SMTI) That Institutions Follow - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc - The National Law Review
2026-05-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc. (SMTI) Stockholders to Inquire about Securities Investigation | NDAQ:SMTI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Investors to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sanara MedTech: From Cash Burner To Profitable Growth (NASDAQ:SMTI) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Investors to Reach Out - ACCESS Newswire
Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2026 Earnings Call Transcript - Insider Monkey
Sanara MedTech Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sanara outlines Q2 2026 net revenue of $28.5M-$29.5M while reaffirming $116M-$121M full-year outlook - MSN
Lake Street Maintains Sanara MedTech(SMTI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Sanara MedTech (SMTI) posts Q1 2026 profit as revenue reaches $27.8M - Stock Titan
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Stro - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sanara MedTech (SMTI) Reports Strong Q1 Revenue Growth and Impro - GuruFocus
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Reach Out | NDAQ:SMTI | Press Release - Stockhouse
Earnings call transcript: Sanara MedTech Q1 2026 beats EPS expectations, stock surges - Investing.com
Earnings call transcript: Sanara MedTech Q1 2026 beats EPS expectations, stock surges By Investing.com - Investing.com South Africa
Transcript: Sanara MedTech Q1 2026 Earnings Conference Call - Benzinga
Sanara MedTech Sees 2Q Rev $28.5M-$29.5M >SMTI - Moomoo
Sanara MedTech Q1 2026 Earnings Call Transcript - MarketBeat
Sanara MedTech's Surgical Pivot Delivers Q1 Profitability - BriefGlance
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Sanara Medtech earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Is Sanara MedTech (SMTI) Undervalued After a Q1 2026 Earnings Be - GuruFocus
Sanara MedTech Reports Q1 2026: Revenue $27.8M, GAAP Net Income $0.05/share, Adjusted EBITDA $4.3M - TradingView
Sanara MedTech Q1 revenue rises, swings to profit - TradingView
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited) - The Manila Times
Sanara MedTech Backs 2026 Rev $116M-$121M >SMTI - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Connect - ACCESS Newswire
2026-05-11 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Connect | NDAQ:SMTI | Press Release - Stockhouse
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Report Preview: What To Expect - GuruFocus
Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-05-10 | Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SMTI | Press Release - Stockhouse
Sanara Medtech Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Sanara MedTech outlines 2026 net revenue guidance of $116M–$121M while expanding distributor network and product reach - MSN
Sanara MedTech faces securities fraud probe after $31.2M loss and program shutdown. - Pluang
SMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
2,804 SMTI restricted shares granted to controller Ashley Mackey - Stock Titan
How Sanara MedTech (SMTI) Is Reframing Its Growth Story Around A Steady US$34 Target - Yahoo Finance
SMTI SEC FilingsSanara Medtech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sanara Medtech Inc Stock (SMTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):